Skip to main content

Year: 2022

Parsons Continues Dedication to Veterans

Company Receives HIRE Vets Medallion Program Award From Department of Labor CENTREVILLE, Va., Nov. 11, 2022 (GLOBE NEWSWIRE) — As the world continues recognizing the important role of veterans across society, Parsons Corporation (NYSE: PSN) announced today several awards and milestones highlighting the company’s ongoing commitment to empowering veterans and maintaining a culture that prioritizes mission, camaraderie, and service. Parsons’ efforts on veterans’ affairs have focused on hiring and retaining veterans and supporting the LGBTQ+ community of active servicemembers and military veterans through the Modern Military Association of America (MMAA). “I’m immensely proud that nearly 25% of our U.S. employees are veterans, demonstrating the commitment Parsons holds in championing our transitioning servicemembers and providing a...

Continue reading

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ~ Initiated U.S. Commercial Launch of PEDMARK® in October 2022 ~ ~ Closed $25 Million in Funding from Petrichor to Support the U.S. Commercialization of PEDMARK®, With the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company focused on the development of PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic...

Continue reading

Interim Management Statement covering Q1 2022/23

Interim Management Statement covering Q1 2022/23 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the first quarter (1 July 2022– 30 September 2022) of the financial year 2022/23. Q1 highlightsIn Q1 of the financial year 2022/23, the revenue amounted to DKK 5,5 million (DKK 5,6 million in Q1 2021/22).Q1 EBITDA amounts to DKK 0,0 million (DKK 0,1 million in Q1 2021/22).Rovsing has had a busy Q1 conducting contract negotiations as many tenders have been awarded following the summer break, here our position in the market has been proven strong, showcased by award of contracts by Astroscale, Airbus Defence and Space, Thales Alenia Space and Jena-Optronik in support of a range of Earth Observation, Science and Commercial missions such as ELSA-M, ARIEL, LSTM, CRISTAL, CIMR and Mars...

Continue reading

Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced two upcoming presentations at the Society for Neuro-Oncology (SNO) annual meeting, being held from November 16-20, 2022 in Tampa, FL. Details are as follows: Title: FIREFLY-1 (PNOC026): Phase 2 Study of Pan-RAF Inhibitor Tovorafenib in Pediatric and Young Adult Patients with RAF-altered Recurrent or Progressive Low-grade Glioma or Advanced Solid TumorsFormat: Poster presentationAbstract Number: CTNI-68Date and Time: Friday, November 18, 2022; 7:30 PM – 9:30 PM ET Location: West/Central Hall Presenter: Lindsay Kilburn, MD, Children’s National Medical Center Title:...

Continue reading

Pennant to Participate in the 2022 Stephens Annual Investment Conference

EAGLE, Idaho, Nov. 11, 2022 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it will participate in the upcoming 2022 Stephens Annual Investment Conference on November 11, 2022. Brent Guerisoli, Chief Executive Officer, John Gochnour, President and Chief Operating Officer, and Jennifer Freeman, Chief Financial Officer, will participate in a fireside chat that day at 11:00 a.m. Eastern Time. A live webcast of the event will be accessible on the Investor Relations section of Pennant’s website at http://investor.pennantgroup.com. About Pennant The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through 95 home health and hospice agencies...

Continue reading

REMINDER – Saputo Inc.: Fiscal 2023 Second Quarter Results

MONTREAL, Nov. 11, 2022 (GLOBE NEWSWIRE) — Saputo Inc. (TSX:SAP) – Saputo will release its fiscal 2023 second quarter financial results on Thursday, November 10, 2022. A press release will be issued after markets close, and a conference call is scheduled on Friday, November 11, 2022, at 8:30 a.m. (Eastern Time) to discuss the Company’s results. The webcast will begin with a short presentation followed by a question and answer period. The speakers will be Mr. Lino A. Saputo, Chair of the Board, President and Chief Executive Officer and Mr. Maxime Therrien, Chief Financial Officer and Secretary. To participate:Webcast: https://www.gowebcasting.com/12252Presentation slides will be included in the webcast and can also be accessed in the “Investors” section of Saputo’s website (www.saputo.com), under “Calendar of Events”.Conference...

Continue reading

FTAI Aviation Ltd. Announces Closing of Merger Transaction

NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (NASDAQ: FTAI), a Cayman Islands exempted company (“FTAI” or the “Company”), announced today the closing of a previously announced merger transaction by and among FTAI, Fortress Transportation and Infrastructure Investors LLC and FTAI Aviation Merger Sub LLC. The execution of a definitive merger agreement outlining the terms of the transaction was initially announced on August 15, 2022. As a result of the merger, shares of Fortress Transportation and Infrastructure Investors LLC were exchanged automatically for shares of FTAI without any further action from the shareholders and Fortress Transportation and Infrastructure Investors LLC became a subsidiary of FTAI. The ordinary shares and preferred shares of the Company continue to trade on Nasdaq under the ticker symbols...

Continue reading

Ceres Acquisition Corp. Reports Third Quarter 2022 Financial Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR OTHER DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 11, 2022 (GLOBE NEWSWIRE) — Ceres Acquisition Corp. (NEO: CERE.U, CERE.WT; OTCQX: CERAF) (“Ceres” or the “Corporation”) is reporting its financial results as at September 30, 2022 and September 30, 2021, and for the three and nine month periods then ended. The Corporation’s unaudited financial statements, along with the accompanying management’s discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval (SEDAR) and may be viewed by interested parties under the Corporation’s profile at www.sedar.com. The Corporation is confident in its abilities to identify, evaluate and execute an attractive qualifying transaction by continuing to leverage its network to source a wide spectrum of meaningful...

Continue reading

Form 8.3 – [EMIS Group plc – 10 11 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Invesco Ltd.: Form 8.3 – Euromoney Institutional Investors PLC

FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Invesco Ltd.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Euromoney Institutional Investor PLC  (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.